Ant Group Achieves Carbon Neutrality in Its Own Operations With Green Computing Technologies Driving Indirect Emission Cuts
19.4.2022 16:31:00 EEST | Business Wire | Press release
Ant Group today announced it has achieved carbon neutrality in its own operations (Scopes 1 & 2), according to 2021 emission figures certified by the China Environmental United Certification Center (CEC). This marks the Company’s first major step towards fulfilling the commitments it made in March 2021 to achieve net zero in carbon emissions by 2030, including providing periodic updates on its progress towards achieving this important goal.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220419005649/en/
Ant Group achieved Scopes 1 & 2 carbon neutrality in its own operations in 2021 (Graphic: Business Wire)
According to CEC certified figures, in 2021, Ant Group reduced a total of 37,909.87 tons of CO2e, equivalent to taking 15,000 cars off the road each year, assuming each car is driven 12,000 kilometers per year at 0.203 kilogram of CO2e per kilometer.
To validate its results, the CEC used Carbon Matrix, AntChain’s software-as-a-service (SaaS) product that helps businesses and institutions track and certify corporate carbon emissions on blockchain. The CEC was an official service provider to the 2022 Winter Olympics, measuring the Olympic Committee’s carbon reduction effectiveness.
In 2021, Ant Group achieved carbon neutrality in its own operations (Scopes 1 & 2) through a combination of reductions, substitutions and offsets:
- Reduction: reduced 1,668.60 tons of CO2e by improving its energy savings and efficiency practices.
- Substitution: avoided 21,883.63 tons of CO2e through the use of renewable energy.
- Offset: offset 23,159.54 tons of CO2e through the purchase of China Certified Emission Reductions (CCERs).
“This is a major milestone since we announced our carbon neutrality goal on March 12, 2021,” said Yijie Peng, Vice President of Ant Group. “Leveraging innovative technologies such as blockchain and green computation, we are well underway to achieve an inclusive, green and sustainable future.”
According to Ant Group’s carbon neutrality roadmap, by 2030, the Company will achieve net zero carbon emissions across Scopes 1, 2 and 3. Scope 1 refers to direct emissions as a result of fossil fuel burning from sources Ant Group owns or controls. Scope 2 refers to indirect emissions associated with the purchase of electricity and the use of heating or cooling networks. Scope 3 refers to all other carbon emissions generated along Ant Group’s value chain, such as the use of data centers, business travel and daily commute programs provided by the Company.
In 2021, Ant Group reduced a total of 36,241.27 tons of CO2e in Scope 3, of which the adoption of green computing technologies contributed to 29,591.48 tons – or about 82% of all the Scope 3 reduction.
Data centers, which are at the core of today’s digital economy, consume a large amount of electricity and generate considerable carbon emissions. Following the adoption of green computing technologies in 2019 – such as online-offline hybrid deployment, cloud-native time-shared scheduling, AI-based auto scaling and OceanBase enterprise-level distributed relational database – Ant Group more than doubled the utilization rates of data servers in three years, while meaningfully reducing its carbon footprint.
Ant Group’s remaining Scope 3 carbon emission reductions came from sourcing environmentally friendly office supplies, and encouraging employees to take public transportation or shared rides – including taxis and carpooling for local business travel.
The CEC’s carbon neutrality certificate for Ant Group (in Chinese language only) is publicly available on the Information Platform for Carbon Neutrality, which is affiliated with the Environmental Development Center of China’s Ministry of Ecology and Environment.
About Ant Group
Ant Group aims to create the infrastructure and platform to support the digital transformation of the service industry. It strives to enable all consumers and small and micro businesses to have equal access to financial and other services that are inclusive, green and sustainable.
For more information, please visit our website at www.antgroup.com or follow us on Twitter @AntGroup.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220419005649/en/
Contact information
Media Enquiries
Le SHEN
Shenle.sl@antgroup.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen Launches AI-Powered RenSuper™ Platform and Industry-First Fully Automated Antibody Discovery Infrastructure26.5.2026 15:00:00 EEST | Press release
Biocytogen today announced the launch of RenSuper Workstation, a next-generation AI-powered antibody discovery platform providing off-the-shelf access to a large-scale, experimentally validated library of fully human therapeutic antibody sequences, together with the RenSuper High-Throughput Antibody Manufacturing Automation Center, a fully automated infrastructure designed to accelerate antibody validation and production. Built on Biocytogen’s proprietary RenMice® platforms, RenSuper establishes a closed-loop antibody discovery engine combining in vivo immune repertoires, AI-driven candidate selection, automated experimental validation, and scalable manufacturing infrastructure. The platform supports the discovery and development of monoclonal antibodies, bispecifics, multispecifics, antibody-drug conjugates (ADCs), VHHs, and other advanced therapeutic modalities, significantly reducing the time and risk associated with antibody discovery. RenSuper Workstation: AI-Powered One-Click Tar
ViaLase Announces Global Commercial Introduction of the FLIGHT Procedure26.5.2026 15:00:00 EEST | Press release
ViaLase, Inc., a commercial stage medical technology company pioneering incision-free, laser-based solutions for glaucoma, today announced the successful completion of the first commercial FLIGHT procedures performed at Centre for Sight in London by Sheraz Daya, MD, and Gus Gazzard, MD, and at Breyer, Kaymak & Klabe Augenchirurgie in Düsseldorf, Germany, by Karsten Klabe, MD. The first commercial FLIGHT procedures were performed using the ViaLuxe® Laser System to deliver an incision-free, image-guided femtosecond laser treatment designed to create precise channels through the trabecular meshwork to restore aqueous outflow and reduce intraocular pressure in patients with open-angle glaucoma. “Centre for Sight has always been committed to bringing meaningful innovation to patients through technologies that advance precision, safety, and the overall treatment experience,” said Sheraz Daya, MD, Medical Director and Founder of Centre for Sight. “We are proud to be the first center globally
BioIVT to Spotlight ADME-Tox Expertise and Solutions at Summer 2026 Events26.5.2026 15:00:00 EEST | Press release
BioIVT, the leading biospecimen solutions provider and global research partner for drug and diagnostic development, today announced it will showcase its broad portfolio of ADME-Tox solutions and research expertise at several leading industry events, including the 2026 MPS World Summit and the ISSX 16th European Meeting. The MPS World Summit takes place May 26-May 29, 2026, in Washington, D.C. BioIVT colleagues will be available at booth #115 to discuss research questions and needs, including preparation, handling, and utilization of the high-quality tissues and cells needed for microphysiological systems (MPS), as well as conducting ADME studies and bioanalysis. BioIVT offers an extensive range of control and disease state biospecimens, including SPHEROID CERTIFIED™ Hepatocytes as well as advanced HEPATOPAC® co-cultures and HEPATOMUNE® tri-cultures. Additionally, Christian Smith, Scientist I, R&D at BioIVT will present a poster titled "Therapeutic Reversal of Established Steatosis Usin
IHS Towers Publishes 2025 Sustainability Report26.5.2026 13:34:00 EEST | Press release
IHS Holding Limited (NYSE: IHS) (“IHS Towers”) group, one of the largest independent owners, operators, and developers of shared communications infrastructure in the world by tower count, has today published its 2025 Sustainability Report. The report covers sustainability activities from January 1, 2025 to December 31, 2025 and demonstrates IHS Towers’ continued commitment to its stakeholders, including, but not limited to, its employees, customers, suppliers, local communities, regulators, governments and shareholders. IHS Towers’ vision is to help create a connected world, where mobile connectivity promotes continued economic growth and social development. The communications infrastructure it provides is vital to enabling that connectivity. In 2025, IHS Towers continued to advance its four-pillar sustainability strategy – focusing on ethics and governance, environment and climate change, education and economic growth, our people and communities – as detailed in this report. Sam Darwi
Compass Pathways to Participate in Jefferies Global Healthcare Conference on June 3, 202626.5.2026 13:30:00 EEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will attend the Jefferies Global Healthcare Conference on June 3, 2026 and will participate in a fireside chat at 12:45pm ET. A live audio webcast of this event will be accessible from the “Events” page of the Investors section of the Compass website. A replay of the webcast will be accessible for 30 days following each event. About Compass Pathways Compass Pathways plc (Nasdaq: CMPS) is a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. We are motivated by the need to find better ways to help and empower people with serious mental health conditions who are not helped by existing treatments. We are pioneering a new paradigm for treating mental health conditions focused on rapid and durable responses through the development of our investigational CO
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
